ARV Group (N=551)

The likelihood of new neurocognitive complications, remission of such complications, or fluctuating patterns of complications were hypothesized to be related to several key variables. These variables include whether or not virus is suppressed in the CSF compartment, whether or not the individual is currently on treatment, the history of past treatment, and whether or not a particular neurological complication has already occurred. To determine the importance of these influences on changes in neurocognitive and neurological complications, we followed longitudinally a series of cases termed "Group A".

Group A consists of individuals characterized by the following variables:

History of HAART; Whether or not virus is detectable in the CSF; Presence or absence of neurocognitive complications at the beginning of the study.

It was anticipated that careful six monthly observation of these groups would reveal the degree to which HAART history and viral suppression predict near future onset of neurological complications; and secondly, would shed light on some of the intermediate steps in this link, for example, evolution of resistant virus in the CSF compartment.

  Cross-sectional 1st Longitudinal
Age 43.05 (8.53) 43.97 (8.48)
Education 12.54 (2.57) 12.75 (2.57)
Gender (% male) 77% 79%
Caucasian 39.7% 43.1%
Hispanic 9.4% 10.9%
African American 48.2% 43.1%
Other 2.6% 2.9%
% AIDS 62.6% 61.8%
CD4 463 (264 - 607) 489 (296 - 632)
Log 10 Plasma HIV RNA 2.13 (1.70 - 3.97) 1.75 (1.70 - 3.75)
Log10 CSF HIV RNA 1.70 (1.70 - 2.28) 1.70 (1.70 - 2.04)
NP Impairment (% impaired) 48% 37%

Horizontal Tabs

This page is associated with a larger collection of pages. You can view them as a whole here.